Takayama K, Nagai T, Kinugasa E, Akizawa T, Koshikawa S
Department of Internal Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan.
ASAIO Trans. 1991 Jul-Sep;37(3):M187-8.
The effects of recombinant human erythropoietin (rHuEPO) on endothelial vasoactive substances were evaluated in 19 regular hemodialysis patients. Blood cell counts, plasma endothelin (ET), alpha-human atrial natriuretic peptide (ANP), platelet activating factor (PAF), 6-keto-prostaglandin F1 alpha (PGF1 alpha), and 11-dehydro-thromboxane B2 (TXB2) were evaluated before rHuEPO treatment; at 4, 8, and 12 weeks during treatment; and 5 weeks after the end of treatment. PAF and TXB2 remained unchanged during the study period, PGF1 alpha and ET significantly increased, and ANP decreased along with an improvement in the anemia. Since endothelial vasoactive substances changed significantly during rHuEPO therapy, the correction of anemia with rHuEPO may affect endothelium.
在19例常规血液透析患者中评估了重组人促红细胞生成素（rHuEPO）对内皮血管活性物质的影响。在rHuEPO治疗前、治疗期间的第4、8和12周以及治疗结束后5周评估血细胞计数、血浆内皮素（ET）、α-人心房利钠肽（ANP）、血小板活化因子（PAF）、6-酮-前列腺素F1α（PGF1α）和11-脱氢血栓烷B2（TXB2）。在研究期间，PAF和TXB2保持不变，PGF1α和ET显著增加，ANP随着贫血的改善而下降。由于在rHuEPO治疗期间内皮血管活性物质发生了显著变化，因此用rHuEPO纠正贫血可能会影响内皮。
